Literature DB >> 21334711

Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity.

Véronique Taché1, D Yvette LaCoursiere, Aasia Saleemuddin, Mana M Parast.   

Abstract

Overexpression of soluble vascular endothelial growth factor receptor-1 has been linked to preeclampsia and is thought to be secondary to placental insufficiency caused by hypoxia. Villous hypermaturity, characterized by presence of increased syncytial knots, has been associated with syndromes of placental insufficiency, particularly when severe. This study was undertaken to determine whether there is a link between soluble vascular endothelial growth factor receptor-1 expression, villous hypermaturity, and clinical severity of preeclampsia. We conducted a retrospective cohort study in which 48 placentas were selected from pathology archives (hypertensive group). Of these, 6 had chronic hypertension, 15 had mild preeclampsia, 14 had severe preeclampsia, and 13 had hemolysis, elevated liver enzymes, and low platelets syndrome. These were compared with 55 placentas from normotensive patients (control group). One representative section of placental parenchyma from each case was stained with an antibody to vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 and given a score based on extent and intensity of staining, representing expression level. Assignment of staining score was done, blinded to clinical history and pathologic diagnosis. Vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 staining was seen in placental syncytiotrophoblasts and was particularly strong in syncytial knots. There was a positive association between vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 staining score and severity of clinical hypertensive state, small placental size, and villous hypermaturity. The association between vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 score and small placentas did not persist after controlling for hypermaturity. Vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 overexpression in the placenta strongly correlates with both severity of hypertensive disease and villous hypermaturity. The correlation with villous hypermaturity further links hypoxia to vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 production in the placenta.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334711     DOI: 10.1016/j.humpath.2010.11.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  11 in total

1.  MTA3 regulates differentiation of human cytotrophoblast stem cells.

Authors:  Mariko Horii; Matteo Moretto-Zita; Katharine K Nelson; Yingchun Li; Mana M Parast
Journal:  Placenta       Date:  2015-07-15       Impact factor: 3.481

Review 2.  Trophoblast lineage-specific differentiation and associated alterations in preeclampsia and fetal growth restriction.

Authors:  Omar Farah; Calvin Nguyen; Chandana Tekkatte; Mana M Parast
Journal:  Placenta       Date:  2020-02-13       Impact factor: 3.481

3.  Can placental growth factors explain birthweight variation in offspring of women with type 1 diabetes?

Authors:  Siobhan Bacon; Dylan Burger; Mayur Tailor; J Johanna Sanchez; George Tomlinson; Helen R Murphy; Denice S Feig
Journal:  Diabetologia       Date:  2021-04-10       Impact factor: 10.122

4.  Induction of the PPARγ (Peroxisome Proliferator-Activated Receptor γ)-GCM1 (Glial Cell Missing 1) Syncytialization Axis Reduces sFLT1 (Soluble fms-Like Tyrosine Kinase 1) in the Preeclamptic Placenta.

Authors:  Brooke Armistead; Leena Kadam; Emily Siegwald; Fergus P McCarthy; John C Kingdom; Hamid-Reza Kohan-Ghadr; Sascha Drewlo
Journal:  Hypertension       Date:  2021-05-24       Impact factor: 9.897

5.  Protein profiling of preeclampsia placental tissues.

Authors:  Chang Shu; Zitao Liu; Lifeng Cui; Chengguo Wei; Shuwen Wang; Jian Jenny Tang; Miao Cui; Guodong Lian; Wei Li; Xiufen Liu; Hongmei Xu; Jing Jiang; Peng Lee; David Y Zhang; Jin He; Fei Ye
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

6.  Isobaric tag for relative and absolute quantitation based quantitative proteomics reveals unique urinary protein profiles in patients with preeclampsia.

Authors:  Wenyan Ding; Bintao Qiu; David S Cram; Xiuting Chen; Shengjie Li; Xiya Zhou; Juntao Liu; Zhihong Wu; Yijun Song
Journal:  J Cell Mol Med       Date:  2019-06-24       Impact factor: 5.310

Review 7.  Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling.

Authors:  Ross McNally; Abdelrahim Alqudah; Danilo Obradovic; Lana McClements
Journal:  Curr Hypertens Rep       Date:  2017-10-23       Impact factor: 5.369

8.  Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles.

Authors:  Michelle O'Brien; Dora Baczyk; John C Kingdom
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

9.  Syncytiotrophoblast extracellular microvesicle profiles in maternal circulation for noninvasive diagnosis of preeclampsia.

Authors:  Lisa Levine; Andreas Habertheuer; Chirag Ram; Laxminarayana Korutla; Nadav Schwartz; Robert W Hu; Sanjana Reddy; Andrew Freas; Patrick D Zielinski; Joey Harmon; Sudheer Kumar Molugu; Samuel Parry; Prashanth Vallabhajosyula
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

Review 10.  Fetal Growth Restriction: Does an Integrated Maternal Hemodynamic-Placental Model Fit Better?

Authors:  F Mecacci; L Avagliano; F Lisi; S Clemenza; Caterina Serena; S Vannuccini; M P Rambaldi; S Simeone; S Ottanelli; F Petraglia
Journal:  Reprod Sci       Date:  2020-11-19       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.